Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions
Mov Disord
.
2020 Oct;35(10):1890-1891.
doi: 10.1002/mds.28279.
Authors
Roisin Sullivan
1
,
Wai Yan Yau
1
2
,
Viorica Chelban
1
2
,
Salvatore Rossi
1
,
Emer O'Connor
1
2
,
Nicholas W Wood
2
3
,
Andrea Cortese
1
4
,
Henry Houlden
1
2
Affiliations
1
Department of Neuromuscular Disease, Queen's Square Institute of Neurology, London, United Kingdom.
2
The National Hospital for Neurology and Neurosurgery, Queen's Square, London, United Kingdom.
3
Movement Disorders, Queen's Square Institute of Neurology, London, United Kingdom.
4
Department of Brain and Behavioural Science, University of Pavia, Pavia, Italy.
PMID:
33068477
DOI:
10.1002/mds.28279
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Atrophy
Humans
Levodopa / therapeutic use
Multiple System Atrophy*
Parkinsonian Disorders* / drug therapy
Parkinsonian Disorders* / genetics
Substances
Levodopa
Grants and funding
MR/T001712/1/MRC_/Medical Research Council/United Kingdom
WT_/Wellcome Trust/United Kingdom
DH_/Department of Health/United Kingdom